Prognostic microRNAs modulate the RHO adhesion pathway: A potential therapeutic target in undifferentiated pleomorphic sarcomas

XPO1, therapeutic … and prognostic target in sarcomas

In a recent issue of Oncotarget [1], Nakayama et al. showed the anti-tumor activity of selinexor, an inhibitor of exportin 1, against a wide variety of sarcoma preclinical models, including several pathological subtypes of soft tissue sarcomas (STS). STS, which amount to less than 2% of adult cancers are a heterogeneous disease with ~50 different pathological subtypes [2]. Surgery is the main t...

Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas

BACKGROUND Until now, almost nothing is known about the tumorigenesis of atypical fibroxanthoma (AFX) and pleomorphic dermal sarcoma (PDS). Our hypothesis is that AFX is the non-infiltrating precursor lesion of PDS. MATERIALS AND METHODS We performed the world-wide most comprehensive immunohistochemical and mutational analysis in well-defined AFX (n=5) and PDS (n=5). RESULTS In NGS-based mu...

Diagnostic, Prognostic and Therapeutic Aspects of Endometrial Stromal Sarcomas, Low Grade and Undifferentiated Endometrial Sarcoma

LAT-derived microRNAs in HSV-1 target SMAD3 and SMAD4 in TGF-β/Smad signaling pathway

Background: During its latent infection, HSV-1 produces only a miRNA precursor called LAT, which encodes six distinct miRNAs. Recent studies have suggested that some of these miRNAs could target cellular mRNAs. One of the key cell signaling pathways that can be affected by HSV-1 is the TGF-β/Smad pathway. Herein, we investigated the potential role of the LAT as well as three LAT-derived miRNAs ...

SPARC: A Potential Prognostic and Therapeutic Target in Pancreatic Cancer

Pancreatic cancer is a complex and heterogeneous disease that often lacks disease-specific symptoms in early stages. The malignancy is currently the fourth leading cause of cancer-related death in Western countries. In advanced stages, the overall 5-year survival is less than 1% to 2%. Most available treatments lack convincing cost-efficiency determinations and are generally not associated with...